...Jane E. Rogers; Xuemei Wang; Allison Trail; Jaffer A. Ajani Background: Platinum + fluoropyrimidine is a standard front-line therapy for unresectable gastroesophageal adenocarcinoma (GA). Subsequent therapy recommendations are ramucirumab + paclitaxel (RAM/PAC), taxane, irinotecan, or trifluridine...

... and safety of irinotecan retreatment (IRI2) in patients with refractory mCRC. Methods: We performed a retrospective analysis of patients with mCRC who were retreated with irinotecan-based regimens. The retreatment regimens with anti-epidermal growth factor receptor therapies were excluded. Results: A total...

... Mesothelioma guidelines, have been inadequate. To explore treatment options for such patients, we performed this retrospective study of patients who received irinotecan plus gemcitabine as second-line therapy for MPM. Methods: We investigated 62 patients diagnosed with unresectable MPM between January 2008...

... a low dose of irinotecan given as a long-term infusion is expected to enhance antitumor activity. We conducted a randomized phase II study to compare oral S-1 with a 24-h infusion of irinotecan plus bevacizumab versus FOLFIRI plus bevacizumab. Methods: The subjects comprised 120 chemotherapy-naïve...

... irinotecan, taxane, and ramucirumab). Recently, anti-programmed death-1 (anti-PD-1) inhibitors have been used with limited efficacy in select patients with adenocarcinoma. Similarly, irinotecan-based therapy has marginal efficacy. We combined irinotecan plus a fluoropyrimidine with an anti-PD-1 antibody...

...) of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as a neoadjuvant chemotherapy in patients with locally advanced rectal cancer. Method: Patients received irinotecan and oxaliplatin (85 mg/m 2 ) on day 1, and capecitabine (1,000 mg/m 2 orally twice daily) on days 1–7 of a biweekly schedule...

...) patients. This study aimed to compare Pmab and Cmab according to the interval between bevacizumab discontinuation and anti-EGFR antibody initiation (bevacizumab-free interval; BFI). Methods: We retrospectively evaluated mCRC patients who received Cmab or Pmab in combination with irinotecan at two...

... with irinotecan plus cisplatin has shown promise in chemo-naïve small-cell lung cancer (SCLC) patients. However, irinotecan treatment for relapsed or refractory SCLC has not been adequately evaluated. This phase II study evaluated the appropriate treatment schedule of irinotecan as a single agent. This study...

... Delconte; Filippo de Braud; Vincenzo Mazzaferro; Maria Di Bartolomeo Objectives: This phase II trial was aimed at assessing the safety and activity of capecitabine, oxaliplatin, and irinotecan (COI regimen) as a preoperative treatment for resectable gastric cancer (GC) or gastroesophageal junction (GEJ...

...Finn Ole Larsen; Alice Markussen; Dorte Nielsen; Bonnie Colville-Ebeling; Lene B. Riis; Benny V. Jensen Objective: The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic...

...Giulia Pasquini; Enrico Vasile; Chiara Caparello; Caterina Vivaldi; Gianna Musettini; Monica Lencioni; Iacopo Petrini; Lorenzo Fornaro; Alfredo Falcone Purpose: The aim of this study was to evaluate the activity of the combination of 5-fluorouracil/folinic acid and irinotecan (FOLFIRI) as third...

...Sotaro Sadahiro; Toshiyuki Suzuki; Akira Tanaka; Kazutake Okada; Gota Saito; Akemi Kamijo Objectives: Protracted low-dose infusion of irinotecan has been suggested to enhance antitumor activity. A phase II study was conducted to evaluate the safety and efficacy of oral S-1 combined with 24-hour...

...Marie Chaix; Julie Vincent; Véronique Lorgis; François Ghiringhelli Purpose: Fluoropyrimidines, oxaliplatin, irinotecan and targeted therapies represent the standard treatment of metastatic colorectal cancer. After failure of all these treatments, few options are available. In such chemorefractory...

... of the Clinical Study Group of Osaka University (CSGO), Colorectal Group Objective: Combined chemotherapy with S-1 and irinotecan (IRIS) for metastatic colorectal cancer has been reported to be effective and safe. However, there are only a few studies on the effects of adding bevacizumab to IRIS. We conducted...

...Ioannis D. Xynos; Maria L. Karadima; Ioannis F. Voutsas; Sousana Amptoulach; Elias Skopelitis; Christos Kosmas; Angelos D. Gritzapis; Nikolas Tsavaris Objective: To identify changes in peripheral immune responses in patients with metastatic colorectal cancer (mCRC) treated with irinotecan/5...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Colorectal cancer Oxaliplatin Irinotecan FOLFOX6 FOLFIRI FIREFOX Neurotoxicity Colorectal cancer is the second...

...Ahmad A. Fora; Jeanne A. McMahon; Greg Wilding; Adrienne Groman; Wen Wee Ma; Karen S. Romano; Marwan G. Fakih Objectives: We conducted a phase II clinical trial of high-dose cetuximab plus irinotecan in KRAS wild-type patients who progressed on standard-dose cetuximab plus irinotecan. Methods...

... Research and Education Objective: S-1 is effective in sequential combination with irinotecan (IRIS) in treating metastatic colorectal cancer. We conducted a randomized phase II trial of modified leucovorin, fluorouracil and irinotecan (mFOLFIRI) + bevacizumab and sequential IRIS + bevacizumab as first...

...Yoon Hee Choi; Tae Won Kim; Kyu-Pyo Kim; Sung Sook Lee; Yong Sang Hong; Min-Hee Ryu; Jae-Lyun Lee; Heung Moon Chang; Baek-Yeol Ryoo; Ho-Sook Kim; Jae-Gook Shin; Yoon-Koo Kang Objectives: We investigated the efficacy and safety of the combination of irinotecan (CPT-11) and S-1 (IRIS regimen...

... (5-FU), leucovorin, irinotecan and oxaliplatin (FOLFOXIRI) in Japanese patients with advanced colorectal cancer. Methods: This phase I dose-finding study was designed to determine the maximum tolerated dose (MTD), recommended dose (RD) or both of FOLFOXIRI. Patients with UDP-glucuronosyltransferase...